A $24.2 million arbitration judgment over legacy PM sensor warranty claims was booked straight against net sales, which is why the top line looks like a 12.8% shortfall while adjusted earnings came in positive for the first time in two years. Strip it out and adjusted sales rose about 30%, with MirrorEye topping $37 million, enough for management to raise 2026 adjusted revenue guidance to $690 million to $700 million, though adjusted EBITDA now lands at the bottom of the $20 million to $25 million range on semiconductor inflation.
Stoneridge Inc
SRI at a Glance
- Market cap
- $165.1M
- Revenue (TTM)
- $896.9M
- Profit margin
- -13.3%
- EPS (TTM)
- $-3.83
- 52-week range
- $5 – $10
- Street target
- $14.50
- Next report
- Nov 4, 2026
Headquartered in Novi, MI Fiscal year ends December NYSE: SRI stoneridge.com
About Stoneridge
Stoneridge, Inc. (NYSE: SRI) is a global supplier of electronic systems and technologies for on- and off-highway vehicles, with a focus on vehicle intelligence, safety and security. Following the January 30, 2026 sale of its Control Devices business, which is now reported as discontinued operations, it operates two reportable segments. Electronics supplies vision systems including the MirrorEye camera monitor system, along with other electronics, primarily to commercial vehicle OEMs in North America and Europe; it also serves off-highway, bus and coach markets. Stoneridge Brazil serves local OEM and aftermarket customers. In 2025, Europe accounted for about 45.5% of sales, North America about 22.7% and South America about 10.3% (excluding Control Devices). The company is extending MirrorEye into autonomous trucks, including deployment on Kodiak AI vehicles, supported by an FMCSA exemption that allows mirrorless designs. Updated
Frequently Asked Questions
What does Stoneridge do?
Stoneridge, Inc. (NYSE: SRI) is a global supplier of electronic systems and technologies for on- and off-highway vehicles, with a focus on vehicle intelligence, safety and security.
What is the SRI stock price target?
The Wall Street consensus 12-month price target for SRI is $14.50.